Helirab-D Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 20 mg, designed for the management of gastrointestinal disorders characterized by acid reflux, dyspepsia, and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the tone of the lower esophageal sphincter and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, providing effective relief from acid-related mucosal damage and promoting ulcer healing. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, optimizing symptom control and improving patient compliance through once-daily dosing. Helirab-D Capsule SR is indicated for the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease, and functional dyspepsia where acid suppression combined with prokinetic action is warranted. Caution is advised in patients with known hypersensitivity to either component, and it should be used under medical supervision, particularly in individuals with underlying cardiac conditions or on concomitant medications that may interact with domperidone or rabeprazole. Regular monitoring and adherence to prescribed dosage are essential to maximize efficacy and minimize adverse effects.